350 related articles for article (PubMed ID: 30935091)
1. HDAC6 Modulates Signaling Pathways Relevant to Synaptic Biology and Neuronal Differentiation in Human Stem-Cell-Derived Neurons.
Iaconelli J; Xuan L; Karmacharya R
Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30935091
[TBL] [Abstract][Full Text] [Related]
2. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
[TBL] [Abstract][Full Text] [Related]
3. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
Beyer M; Kiweler N; Mahboobi S; Krämer OH
Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
[TBL] [Abstract][Full Text] [Related]
4. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
5. Lysine Deacetylation by HDAC6 Regulates the Kinase Activity of AKT in Human Neural Progenitor Cells.
Iaconelli J; Lalonde J; Watmuff B; Liu B; Mazitschek R; Haggarty SJ; Karmacharya R
ACS Chem Biol; 2017 Aug; 12(8):2139-2148. PubMed ID: 28628306
[TBL] [Abstract][Full Text] [Related]
6. The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease.
Cosenza M; Pozzi S
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30096875
[TBL] [Abstract][Full Text] [Related]
7. [Research progress of histone deacetylase 6 inhibitors in the therapy of ischemic stroke].
Zhang CC; Lu F; Liang JQ; Zhou YF
Sheng Li Xue Bao; 2018 Jun; 70(3):301-309. PubMed ID: 29926072
[TBL] [Abstract][Full Text] [Related]
8. HDAC6 in Diseases of Cognition and of Neurons.
LoPresti P
Cells; 2020 Dec; 10(1):. PubMed ID: 33374719
[TBL] [Abstract][Full Text] [Related]
9. Neuronal complexity is attenuated in preclinical models of migraine and restored by HDAC6 inhibition.
Bertels Z; Singh H; Dripps I; Siegersma K; Tipton AF; Witkowski WD; Sheets Z; Shah P; Conway C; Mangutov E; Ao M; Petukhova V; Karumudi B; Petukhov PA; Baca SM; Rasenick MM; Pradhan AA
Elife; 2021 Apr; 10():. PubMed ID: 33856345
[TBL] [Abstract][Full Text] [Related]
10. A novel orally active HDAC6 inhibitor T-518 shows a therapeutic potential for Alzheimer's disease and tauopathy in mice.
Onishi T; Maeda R; Terada M; Sato S; Fujii T; Ito M; Hashikami K; Kawamoto T; Tanaka M
Sci Rep; 2021 Jul; 11(1):15423. PubMed ID: 34326423
[TBL] [Abstract][Full Text] [Related]
11. Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity.
Wu H; Yang K; Zhang Z; Leisten ED; Li Z; Xie H; Liu J; Smith KA; Novakova Z; Barinka C; Tang W
J Med Chem; 2019 Aug; 62(15):7042-7057. PubMed ID: 31271281
[TBL] [Abstract][Full Text] [Related]
12. Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models.
Depetter Y; Geurs S; De Vreese R; Goethals S; Vandoorn E; Laevens A; Steenbrugge J; Meyer E; de Tullio P; Bracke M; D'hooghe M; De Wever O
Int J Cancer; 2019 Aug; 145(3):735-747. PubMed ID: 30694564
[TBL] [Abstract][Full Text] [Related]
13. Restoration of mutant hERG stability by inhibition of HDAC6.
Li P; Kurata Y; Endang M; Ninomiya H; Higaki K; Taufiq F; Morikawa K; Shirayoshi Y; Horie M; Hisatome I
J Mol Cell Cardiol; 2018 Feb; 115():158-169. PubMed ID: 29355491
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in the discovery of potent and selective HDAC6 inhibitors.
Wang XX; Wan RZ; Liu ZP
Eur J Med Chem; 2018 Jan; 143():1406-1418. PubMed ID: 29133060
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase 6 (HDAC6) deacetylates extracellular signal-regulated kinase 1 (ERK1) and thereby stimulates ERK1 activity.
Wu JY; Xiang S; Zhang M; Fang B; Huang H; Kwon OK; Zhao Y; Yang Z; Bai W; Bepler G; Zhang XM
J Biol Chem; 2018 Feb; 293(6):1976-1993. PubMed ID: 29259132
[TBL] [Abstract][Full Text] [Related]
16. HDAC6 inhibitors modulate Lys49 acetylation and membrane localization of β-catenin in human iPSC-derived neuronal cells.
Iaconelli J; Huang JH; Berkovitch SS; Chattopadhyay S; Mazitschek R; Schreiber SL; Haggarty SJ; Karmacharya R
ACS Chem Biol; 2015 Mar; 10(3):883-90. PubMed ID: 25546293
[TBL] [Abstract][Full Text] [Related]
17. Differential regulation of Bdnf expression in cortical neurons by class-selective histone deacetylase inhibitors.
Koppel I; Timmusk T
Neuropharmacology; 2013 Dec; 75():106-15. PubMed ID: 23916482
[TBL] [Abstract][Full Text] [Related]
18. A novel class of anthraquinone-based HDAC6 inhibitors.
Song Y; Lim J; Seo YH
Eur J Med Chem; 2019 Feb; 164():263-272. PubMed ID: 30597327
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of HDAC6 increases acetylation of peroxiredoxin1/2 and ameliorates 6-OHDA induced dopaminergic injury.
Jian W; Wei X; Chen L; Wang Z; Sun Y; Zhu S; Lou H; Yan S; Li X; Zhou J; Zhang B
Neurosci Lett; 2017 Sep; 658():114-120. PubMed ID: 28823893
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma.
Auzmendi-Iriarte J; Saenz-Antoñanzas A; Mikelez-Alonso I; Carrasco-Garcia E; Tellaetxe-Abete M; Lawrie CH; Sampron N; Cortajarena AL; Matheu A
Cell Death Dis; 2020 Jun; 11(6):417. PubMed ID: 32488056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
